Alkermes
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the...
Latest News
21 hours ago · marketbeat.com
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing AheadAlkermes NASDAQ: ALKS is preparing for a series of clinical readouts across its orexin drug programs, with studies in sleep disorders, attention-deficit/hyperactivity disorder and fatigue expected over the next 12 months, CEO Blair Jackson said during a fireside chat.
12 days ago · businesswire.com
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall CongressDUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil) and LUMRYZ® (sodium oxybate) extended-release oral suspension, as well as alixorexton, the company's novel, investigation.
13 days ago · seekingalpha.com
Alkermes plc (ALKS) Q3 2026 Earnings Call TranscriptAlkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson - President, CEO & Director Todd Nichols Joshua Reed - Senior VP & CFO Conference Call Participants Leonid Timashev - RBC Capital Markets, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Rudy Li David Amsellem - Piper Sandler & Co., Research Division David Hoang - Deutsche Bank AG, Research Division Marc Goodman - Leerink Partners LLC, Research Division Alex Nackenoff Umer Raffat - Evercore ISI Institutional Equities, Research Division So Youn Shim - UBS Investment Bank, Research Division Ami Fadia - Needham & Company, LLC, Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Douglas Tsao - H.C.
14 days ago · marketbeat.com
What Alkermes (ALKS) Said on Its Q3 Earnings CallAlkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development portfolio across sleep, neuropsychiatric and neurological disorders.
14 days ago · zacks.com
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
14 days ago · zacks.com
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesAlkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.
14 days ago · businesswire.com
Alkermes plc Reports Third Quarter 2026 Financial ResultsDUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss these financial results and provide an update on the company. The webcast may be accessed.
18 days ago · businesswire.com
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the company's investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD) and for the adjunctive treatment of MDD. “Orexin biology represents a compelling are.
18 days ago · seekingalpha.com
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another StoryAlkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but decline sequentially, with adjusted EPS expected to fall 64.3% due to elevated R&D and SG&A expenses. LUMRYZ's patient growth and LYBALVI's prescription trends are key near-term metrics, while Alixorexton's clinical progress bolsters long-term investment appeal.
27 days ago · businesswire.com
Alkermes to Report Third Quarter Financial Results on November 3, 2026DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webca.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ALKS